ES2810227T3 - Biomarcadores de diabetes - Google Patents

Biomarcadores de diabetes Download PDF

Info

Publication number
ES2810227T3
ES2810227T3 ES13794110T ES13794110T ES2810227T3 ES 2810227 T3 ES2810227 T3 ES 2810227T3 ES 13794110 T ES13794110 T ES 13794110T ES 13794110 T ES13794110 T ES 13794110T ES 2810227 T3 ES2810227 T3 ES 2810227T3
Authority
ES
Spain
Prior art keywords
therapy
cells
central memory
cell
subpopulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13794110T
Other languages
English (en)
Spanish (es)
Inventor
Tihamer Orban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaim Pharma Ltd
Original Assignee
Phaim Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phaim Pharma Ltd filed Critical Phaim Pharma Ltd
Application granted granted Critical
Publication of ES2810227T3 publication Critical patent/ES2810227T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES13794110T 2012-05-24 2013-05-24 Biomarcadores de diabetes Active ES2810227T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Publications (1)

Publication Number Publication Date
ES2810227T3 true ES2810227T3 (es) 2021-03-08

Family

ID=49621783

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13794110T Active ES2810227T3 (es) 2012-05-24 2013-05-24 Biomarcadores de diabetes

Country Status (13)

Country Link
US (5) US20130316375A1 (enExample)
EP (2) EP2856149B1 (enExample)
JP (5) JP6312332B2 (enExample)
KR (1) KR102172285B1 (enExample)
CN (1) CN104520707B (enExample)
AU (4) AU2013266145A1 (enExample)
CA (1) CA2874507A1 (enExample)
DK (1) DK2856149T3 (enExample)
ES (1) ES2810227T3 (enExample)
IN (1) IN2014DN10259A (enExample)
MX (1) MX357169B (enExample)
WO (1) WO2013177505A1 (enExample)
ZA (1) ZA201409006B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN107003315B (zh) * 2014-12-25 2018-09-25 株式会社日立制作所 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
JP7852926B2 (ja) 2020-06-26 2026-04-28 ファイム ファーマ リミテッド 乾癬及び他の自己免疫疾患抗原免疫モジュレータ（ａｉｍ）治療プラットフォーム
WO2022264088A1 (en) 2021-06-17 2022-12-22 Phaim Pharma Ltd. Individualized cell therapy using patient-derived antigen-specific regulatory t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246212A1 (en) * 2005-09-30 2009-10-01 Kyoto University Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
JP7618502B2 (ja) * 2021-05-14 2025-01-21 東京計器株式会社 船舶用自動操舵装置

Also Published As

Publication number Publication date
EP3767295A1 (en) 2021-01-20
JP6312332B2 (ja) 2018-04-18
ZA201409006B (en) 2016-07-27
JP2023011814A (ja) 2023-01-24
AU2013266145A1 (en) 2015-01-15
US20190137483A1 (en) 2019-05-09
AU2023222980A1 (en) 2023-09-21
DK2856149T3 (da) 2020-08-17
KR102172285B1 (ko) 2020-11-02
US20250237643A1 (en) 2025-07-24
JP2018116061A (ja) 2018-07-26
JP2021001899A (ja) 2021-01-07
CN104520707B (zh) 2018-03-27
AU2019200824A1 (en) 2019-04-04
US20230333094A1 (en) 2023-10-19
EP2856149A1 (en) 2015-04-08
AU2019200824B2 (en) 2021-06-24
CA2874507A1 (en) 2013-11-28
IN2014DN10259A (enExample) 2015-08-07
JP2024150702A (ja) 2024-10-23
US20160299128A1 (en) 2016-10-13
MX2014014348A (es) 2015-06-05
CN104520707A (zh) 2015-04-15
US20130316375A1 (en) 2013-11-28
AU2021202609A1 (en) 2021-05-27
JP2015520378A (ja) 2015-07-16
EP2856149A4 (en) 2016-06-01
JP6761827B2 (ja) 2020-09-30
EP2856149B1 (en) 2020-07-08
WO2013177505A1 (en) 2013-11-28
KR20150022878A (ko) 2015-03-04
MX357169B (es) 2018-06-28

Similar Documents

Publication Publication Date Title
US20250237643A1 (en) Diabetes Biomarkers
Sun et al. Two to tango: dialogue between adaptive and innate immunity in type 1 diabetes
Giannopoulou et al. Effect of a single autologous cord blood infusion on beta‐cell and immune function in children with new onset type 1 diabetes: A non‐randomized, controlled trial
RU2702632C2 (ru) Новые комбинации для антигенной терапии
Sheehy et al. Targeting type 1 diabetes: selective approaches for new therapies
Wan et al. Recovery from overt type 1 diabetes ensues when immune tolerance and β-cell formation are coupled with regeneration of endothelial cells in the pancreatic islets
Pietropaolo Persistent C-peptide: what does it mean?
Cari et al. Microencapsulated G3C hybridoma cell graft delays the onset of spontaneous diabetes in NOD mice by an expansion of Gitr+ Treg cells
Bollyky et al. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
JP2024041812A (ja) 改善された免疫療法
Martens et al. Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant
CN117813375A (zh) 选择性耐受-选择性生成耐受性树突状细胞的方法
Di Dedda Targeting the glucose transporter GLUT1 to control T cell activation
Tootee et al. Clinical Outcomes of Fetal Stem Cell Transplantation in Type 1 Diabetes Are Related to Alternations to Different Lymphocyte Populations
Wen et al. A paradigm shift of PD-L1 immunotherapy based on a tracking-to-triggering immunoediting effect of 2-[18F] FDG
Nandedkar Autoantigens and Insulin Receptor in Type 1 Diabetes
Piya et al. Understanding the Immunology of Type 1 Diabetes—An Overview of Current Knowledge and Perspectives for the Future
Keymeulen et al. Predictors of progression to Type 1 diabetes: preparing
Donaghue et al. Research to cure diabetes is now multipronged. A number of studies have focused on predicting risk, which then has allowed development of studies to intervene in the